51
|
Ossakow SL, Papadopoulos K, Orens J, Coffey T. Parallel propagation effects on the type 1 electrojet instability. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/ja080i001p00141] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
52
|
Palmadesso P, Coffey TP, Ossakow SL, Papadopoulos K. Generation of terrestrial kilometric radiation by a beam-driven electromagnetic instability. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/ja081i010p01762] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
53
|
Beeram M, Papadopoulos K, Tolcher A, Rasco D, Cousin T, Itri L, Patnaik A. Tesetaxel: Analysis of Two Dosing Schedules (ONCE WEEKLY VS. EVERY 3 WEEKS) Using a Novel Oral Taxane. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33042-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
54
|
Patnaik A, Papadopoulos K, Tolcher A, Beeram M, Tawashi M, Fournel M, Maroun C, Humphrey R, Besterman J, O'Dwyer P. Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33054-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
55
|
Mita AC, Papadopoulos K, de Jonge MJA, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QSC, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 2011; 105:938-44. [PMID: 21878940 PMCID: PMC3185947 DOI: 10.1038/bjc.2011.332] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 07/22/2011] [Accepted: 08/01/2011] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK) and pharmacodynamics (PD) of higher doses of erlotinib. METHODS Patients initially received erlotinib 150 mg per day. The dose was successively increased in each patient to that associated with a TR. Anticancer activity was evaluated. Plasma, skin, and hair were sampled for PK and PD studies. RESULTS Erlotinib dose escalation to 200-475 mg per day was feasible in 38 (90%) of 42 patients. Twenty-four (57%) patients developed a TR, but 19 (79%) did so at 150 mg per day. Five (12%) patients, all of whom developed a TR, had a partial response. Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051). Neither rash severity nor response correlated with erlotinib exposure. CONCLUSION Intrapatient dose escalation of erlotinib does not appreciably increase the propensity to experience a maximal level of tolerable skin toxicity, or appear to increase the anticancer activity of erlotinib in NSCLC.
Collapse
|
56
|
Papadopoulos K, Mendelson D, Tolcher A, Burris H, Gordon M, Wong H, Bomba D, Lee S, Gillenwater H, Infante J. 1209 POSTER ONX 0912, a Novel Oral Proteasome Inhibitor (PI), in Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70821-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
57
|
Tolcher AW, Bendell JC, Patnaik A, Papadopoulos K, Bellew KM, Cox DS, Xu Y, Burris HA, Le N, Infante JR. A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.278] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
278 Background: GSK1120212 (212) is a reversible, allosteric inhibitor of MEK1/MEK2. The objectives of this open-label, single-arm study are to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of 212 + gemcitabine (gem), and to determine the recommended phase II regimen (RP2R) in patients (pts) with advanced solid tumors. Methods: 212 (1-2.5mg) is given continuously, orally, once daily. Gem (1,000mg/m2) is infused on days 1, 8, and 15 every 28 days. Doses are escalated to the maximum tolerated dose (MTD) and followed by an expansion cohort to confirm the RP2R tolerability. Results: 28 pts received ≥ 1 dose of 212 + gem, including 8 pancreatic, 6 breast, and 4 non-small cell lung (NSCLC) cancer pts. The MTD and RP2R is 2mg 212 + 1,000mg/m2 gem. Dose-limiting toxicities (DLTs) are G3/G4 febrile neutropenia (n=2), G3 AST elevation (n=2), and G2 uveitis (n=1). 16 serious adverse events (SAEs) were reported; 5 were considered to be related to study drugs (1 pneumonitis, 3 febrile neutropenia, 1 dyspnea). All DLTs and SAEs have resolved. The most common AEs at the RP2R (n=18) were rash (78%), fatigue (67%), thrombocytopenia (61%), neutropenia (50%), decreased appetite (50%), nausea (44%), diarrhea and constipation (39%); all ≤ G2 except thrombocytopenia (17% ≥ G3) and neutropenia (33% ≥ G3). Co-administration did not affect the PK profiles of 212 or gem. 25 pts had measurable disease at baseline. 1 pancreatic cancer pt with previous radiotherapy and 2 cycles of gem achieved a partial response and stayed on study for 6 months. 3 additional pancreatic cancer pts reported stable disease; 2 of which were on the study for 3.5-5 months and the third pt continues in the study. 1 triple-negative breast cancer pt, refractory to chemotherapy, and 1 parotid cancer pt experienced a complete response of their target lesions. Conclusions: 212 + gem is tolerable with an acceptable safety profile in this pt population, with evidence of clinical activity in pancreatic cancer. A randomized phase II study in previously untreated patients with metastatic pancreatic cancer is underway to investigate the clinical activity of this combination. [Table: see text]
Collapse
|
58
|
Tolcher A, Patnaik A, Papadopoulos K, Mays T, Stephan T, Humble D, Frohlich M, Sims R. 376 Preliminary results from a Phase 1 study of D-3263 HCl, a TRPM8 calcium channel agonist, in patients with advanced cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72083-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
59
|
Nieves F, Moore M, Mann M, Moskaluk C, Tolcher A, Papadopoulos K, Patnaik A, Kaufman J, Wick M. 154 Establishment and evaluation of patient-derived tumor models of adenoid cystic carcinoma: Effects of chemotherapeutics and targeted therapies on human ACC xenografts. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71859-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
60
|
Shimizu T, Tolcher A, LoRusso P, Papadopoulos K, Patnaik A, Smith L, Keegan M. 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72071-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
61
|
Papadopoulos K, Crippa S, Hanssen A, Montagnoli A, Fiorentini F, Tolcher A, Martignoni M, Isacchi A, Laffranchi B, Patnaik A. 385 A first in human phase 1 study of the safety and pharmacokinetics of a novel Cdc7 inhibitor NMS-1116354, administered orally to patients with solid tumors. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72092-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
62
|
O'Dwyer P, Papadopoulos K, Amaravadi R, Harlacker K, Beeram M, Drouin M, Mehran M, Besterman J, Maroun C, Patnaik A. 396 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with docetaxel: clinical and preclinical experience. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72103-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
63
|
Patnaik A, Besterman J, Tolcher A, Mehran M, Drouin M, Maroun C, Bonfils C, Beeram M, Martell R, Papadopoulos K. 395 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72102-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
64
|
Beeram M, Papadopoulos K, Patnaik A, Qureshi A, Tolcher AW. Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
65
|
Siu LL, Papadopoulos K, Alberts SR, Kirchoff-Ross R, Vakkalagadda B, Lang L, Ahlers CM, Bennett KL, Van Tornout JM. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2501] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
66
|
Brana I, LoRusso P, Baselga J, Heath EI, Patnaik A, Gendreau S, Laird A, Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3030] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
67
|
Thompson DS, Patnaik A, Bendell JC, Papadopoulos K, Infante JR, Mastico RA, Johnson D, Qin A, O'Leary JJ, Tolcher AW. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3058] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
68
|
Rosen PJ, Tolcher AW, Lee P, Smitley M, Fuerst M, Spinelli R, Crippa S, Jannuzzo MG, Comis S, Papadopoulos K. Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
69
|
Lee P, Wong AF, Burris HA, Papadopoulos K, Sausville EA, Rosen PJ, Mendelson DS, Infante JR, Patnaik A, Gordon MS. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
70
|
Shimizu T, Tolcher AW, Patnaik A, Papadopoulos K, Christensen O, Lin T, Blumenschein GR. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3035] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, De Bono JS, Tolcher AW. First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
72
|
Yu MK, Samlowski WE, Baichwal V, Brown B, Evans BA, Woodland D, Mather G, Patnaik A, Tolcher AW, Papadopoulos K. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
73
|
Patnaik A, Weiss GJ, Papadopoulos K, Tibes R, Tolcher AW, Payumo FC, Cotreau MM, Jac J, Isaacs R, Ramanathan RK. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2525] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
74
|
Beeram M, Novick SC, Qureshi A, Patnaik A, Papadopoulos K, Tolcher AW. An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
75
|
Forster MD, Patnaik A, Sandhu SK, Papadopoulos K, Tromp BJ, Messiou C, Balkwill F, Berns B, De Bono JS, Tolcher AW. Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|